XFree™ (Hydratin)
A New Concept For The Treatment of Eczema
Claire Shearwood
Neil Featherstone
Wail Assaad.
Carolyn Furlon...
Introduction
 Eczema is a common disease in the
population
 Treatment is limited and often inadequate
 Hydratin, a new ...
Overview of Eczema
 Eczema is an inflammation of
the skin.
 The severity of the disease
can vary.
 One fifth of childre...
Causes and Symptoms
 Atopic eczema is hereditary and is an
excessive immune response
 Other types of eczema caused by ir...
Current Treatments
• Emolients - reduce water loss
• Topical steroids
• Topical immunomodulators
For serious eczema:
• UV ...
XFree: A new concept in treatment
Intracellular hydration
Biological hybrid
plant (Urtica dioica)
Synergistic
Aims
Assess eczema epidermal cells in a skin
culture system
Determine whether epidermal cells in eczema
have reduced intra...
Methods
Cells continue to replicate in culture permitting study
Epidermal culture system
Epidermis from healthy volunteers...
Microscopy
Epidermal cells loaded with hydration-sensitive indicators
Pseudo-coloured image of
hydrated epidermal cell in-...
Ethics
Royal Liverpool Hospital Trust
has given permission for
epidermal cells to be obtained
from volunteers
Ethical appr...
Timescales
 4 Stages
1. Eczema Histological assay.
2. Development of drug formulations with possible
potency.
3. (in-vitr...
Financial Costing (1)
Category Cost/ year (£) Project cost (£)
Stipends 26,000 78,000
Other Student fees 1200 3600
Lab Cha...
Financial Costing (2)
Project cost
14%
10%
23%
3%
49%
1%
Students
Lab Charges
Consumables
Chemicals
Equipment hire
Volunte...
Collaborating Groups
 2 Major Groups
– Pharmacology
Dermatology
 3 supporting groups
– Physiology
– Chemistry
– Royal Li...
Outcomes
 A new skin cultivation
method will be tested
 A new drug will be produced
 Proof that this drug
successfully ...
PhD Benefits
Academic skills
Subject-specific skills
Communication,
teamwork, networking
Time management
Academic Benefits
Publications
Academic reputation
Transfer of knowledge
Funding for further research
Community Benefits
Reduce treatment
regimens for patients
Less side-effects
Cost-effectiveness
Patients
NHS
SHIRC Benefits
Improve working
relationships
Meets interdisciplinary
policy
Future collaborations
Achievable targets
Summary
Novel study
Benefits to patients,
academia, industry +
SHIRC
Achievable targets
Upcoming SlideShare
Loading in …5
×

View PowerPoint presentation

898 views

Published on

Published in: Technology, Business
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
898
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide
  • Eczema is a common disease in the population and is becoming more so because of increased sensitivity to allergens in the surrrounding environment. Treatment for eczema is limited and often inadequate because the only preventative treatments involve many unpleasant side effects, and are only used in severe cases. Other medications treat the symptoms i.e. itchiness and inflammation, and do not prevent further flare ups. Therefore a preventative drug would be more than welcomed by both patients and medical practitioners. In this proposal we plan to outline the production and testing of a new drug called Hydratin which could revolutionise the treatment of eczema and give relief to millions of sufferers.
  • Eczema is an inflammation of the skin which gives it a red, dry and flaky appearance. The severoty of the disease can vary and depends on the type of eczema that a patient has. It is now a common condition, with one fifth of children and one in twelve adults have the disease. There are a few types of eczema including atopic, allergic contact dermatitis, irritant contact dermatitis, discoid eczema etc. Atopic is the most common and usually the most serious type of eczema.
  • The causes of eczema are many and depend on the particular type of eczema that a person has. Atopic eczema has been found to be genetically linked. Atopic eczema is an excessive reaction by the immune system producing inflamed, irritated and sore skin. The most common symptom of atopic eczema is itchiness, which can be almost unbearable. Scratching causes the skin to break and makes it prone to infection which is a common problem to eczema sufferers. Other associated atopic conditions include asthma and hayfever. Other types of eczema are caused by irritants such as chemicals, nickel and yeast. Other causes of eczema are environment factors and stress. In mild eczema the is dry, hot and itchy and in severe eczema the skin can become broken, raw and bleed.
  • There are many treatments available to treat eczema and an effective skin care routing can minimise discomfort. This includes emolients which reduce water loss to help prevent the dryness normally associated with eczema. Emolients are used all over to maintain moisture levels and come in ointments and oils for the bath. When eczema is under control only emolients are required. When a flare-up occurs topical steroids may be used in varying strengths depending on severity and they act by reducing inflammation. Topical immunomodulators are new treatments that do not contain steroiids and which change the immune system in some way. They are used when steroids have failed in moderate to severe eczema. There are a few treatments which are used only when the patient has severe eczema because of the large number of possible side effects. There treatments inlcude UV light treatment, oral steroids, cyclosporin and a few other immune suppressing drugs .
  • View PowerPoint presentation

    1. 1. XFree™ (Hydratin) A New Concept For The Treatment of Eczema Claire Shearwood Neil Featherstone Wail Assaad. Carolyn Furlong.
    2. 2. Introduction  Eczema is a common disease in the population  Treatment is limited and often inadequate  Hydratin, a new drug to treat eczema?
    3. 3. Overview of Eczema  Eczema is an inflammation of the skin.  The severity of the disease can vary.  One fifth of children, and one in twelve adults have the disease.  There are a few types of eczema, atopic is the most common.
    4. 4. Causes and Symptoms  Atopic eczema is hereditary and is an excessive immune response  Other types of eczema caused by irritants Symptoms: • Mild eczema: the skin is dry, hot and itchy • Severe eczema: the skin can become broken, raw and bleed
    5. 5. Current Treatments • Emolients - reduce water loss • Topical steroids • Topical immunomodulators For serious eczema: • UV light treatment, oral steroids and Cyclosporin.
    6. 6. XFree: A new concept in treatment Intracellular hydration Biological hybrid plant (Urtica dioica) Synergistic
    7. 7. Aims Assess eczema epidermal cells in a skin culture system Determine whether epidermal cells in eczema have reduced intracellular water content Test HydratinTm to hydrate cells in-vitro
    8. 8. Methods Cells continue to replicate in culture permitting study Epidermal culture system Epidermis from healthy volunteers and eczema patients harvested Cultured 37oC, 5% CO2 +/- Hydratin (100uM) Jackson et al. 2003 J Dermatol
    9. 9. Microscopy Epidermal cells loaded with hydration-sensitive indicators Pseudo-coloured image of hydrated epidermal cell in-vitro Cells passively loaded TRX-456 (10uM) Laser confocal microscope Statistical analysis
    10. 10. Ethics Royal Liverpool Hospital Trust has given permission for epidermal cells to be obtained from volunteers Ethical approval will be sought for trials of HydratinTm at later stages of the study
    11. 11. Timescales  4 Stages 1. Eczema Histological assay. 2. Development of drug formulations with possible potency. 3. (in-vitro) Testing the different drugs with the histological assay. 4. (in-vivo) Controlled clinical trials.
    12. 12. Financial Costing (1) Category Cost/ year (£) Project cost (£) Stipends 26,000 78,000 Other Student fees 1200 3600 Lab Charges 7000 21,000 Consumables 5000 15000 Chemicals 17500 35000 Equipment hire 1500 4500 Volunteers 1500 1500 Total 158,600 (171,288)
    13. 13. Financial Costing (2) Project cost 14% 10% 23% 3% 49% 1% Students Lab Charges Consumables Chemicals Equipment hire Volunteers
    14. 14. Collaborating Groups  2 Major Groups – Pharmacology Dermatology  3 supporting groups – Physiology – Chemistry – Royal Liverpool Hospital Pharmacology Dermatology PhysiologyChemistry Liverpool Royal Hospital
    15. 15. Outcomes  A new skin cultivation method will be tested  A new drug will be produced  Proof that this drug successfully treats Eczema  Improve the lives of millions
    16. 16. PhD Benefits Academic skills Subject-specific skills Communication, teamwork, networking Time management
    17. 17. Academic Benefits Publications Academic reputation Transfer of knowledge Funding for further research
    18. 18. Community Benefits Reduce treatment regimens for patients Less side-effects Cost-effectiveness Patients NHS
    19. 19. SHIRC Benefits Improve working relationships Meets interdisciplinary policy Future collaborations Achievable targets
    20. 20. Summary Novel study Benefits to patients, academia, industry + SHIRC Achievable targets

    ×